查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595650

乾癬藥物市場：按治療層級、按治療類型、按作用機制、按給藥途徑、按配銷通路、按應用 - 2025-2030 年全球預測

Psoriasis Drugs Market by Therapeutic Class, Type of Treatment, Mechanism of Action, Route of Administration, Distribution Channel, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年乾癬治療市場價值為96.7億美元，預計到2024年將達到108.3億美元，複合年成長率為12.07%，到2030年將達到214.8億美元。

乾癬藥物的範圍包括一系列旨在控制和緩解乾癬是一種慢性自體免疫疾病，其特徵是皮膚細胞快速增殖，導致脫皮和發炎。全球乾癬盛行率不斷上升，影響數百萬人並極大影響生活品質，這凸顯了對這些藥物的需求。治療方法包括生物製藥、口服全身治療和局部治療，每種治療均根據乾癬的嚴重程度和類型進行客製化。最終的使用範圍主要是在醫院、診所和居家醫療環境中，由於其複雜性，生物製藥通常在臨床環境中使用。

主要市場統計
基準年[2023] 96.7億美元
預測年份 [2024] 108.3億美元
預測年份 [2030] 214.8億美元
複合年成長率（%） 12.07%

影響乾癬藥物市場的主要成長要素包括生物技術研究的進步，導致標靶治療，增加醫療保健支出，以及對乾癬及其治療方案的認知不斷提高。此外，處於臨床試驗各個階段的不斷擴大的藥物管線也帶來了巨大的成長機會。特別是，向以患者為中心的治療的轉變和對個人化醫療的需求正在推動市場潛力，新興國家由於都市化和生活方式的改變導致乾癬率不斷上升。

然而，也存在一些挑戰。生物製藥治療的高成本和藥物核准的嚴格監管要求是主要障礙。此外，低收入地區獲得藥品的機會可能受到限制，進而影響市場滲透率。

創新努力可能包括開發具有成本效益的生物相似藥、提高現有藥物的療效以及探索新的給藥系統以提高患者的依從性。數位健康整合有很多機會，例如用於症狀監測的穿戴式設備，可以促進更好的管理。該市場的特點是技術快速進步以及向更全面和患者友好的治療方法的動態轉變。利用這些創新並解決成本可及性障礙的公司有潛力推動顯著成長，並在這個不斷變化的市場環境中保持競爭力。

市場動態：揭示快速發展的乾癬藥物市場的關鍵市場洞察

供需的動態交互作用正在改變乾癬藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 乾癬盛行率增加
    • 老年人口增加以及斑塊型乾癬和乾癬性關節炎盛行率增加
    • 乾癬藥物的核准流程簡化
  • 市場限制因素
    • 治療費用高
  • 市場機會
    • 乾癬研究和管道藥物開發
  • 市場挑戰
    • 藥物副作用

波特的五力戰略工具駕馭乾癬藥物市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對乾癬藥物市場的影響

外部宏觀環境因素在塑造乾癬治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解乾癬治療藥物市場的競爭狀況

對乾癬治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣乾癬治療市場供應商的績效評估

FPNV 定位矩陣是評估乾癬治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為乾癬治療藥物市場的成功指明道路

對於旨在加強其在全球市場的影響力的公司來說，對乾癬治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 乾癬發生率增加
      • 老年人口增加，斑塊型乾癬和乾癬性關節炎盛行率增加
      • 乾癬藥物的核准流程簡化
    • 抑制因素
      • 治療費用高
    • 機會
      • 乾癬研究和管道藥物增加
    • 任務
      • 藥物副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療層級的乾癬治療藥物市場

  • 白細胞介素抑制劑
  • 腫瘤壞死因子抑制劑

第7章依治療類型分類的乾癬治療藥物市場

  • 生物製藥
  • 小分子全身藥物
  • 熱帶療法

第8章乾癬治療藥物市場（依作用機轉）

  • 白細胞介素抑制劑
  • PDE4抑制劑
  • TNFα抑制劑

第9章乾癬治療藥物市場：依給藥途徑

  • 口服
  • 胃腸外的
  • 話題

第10章乾癬治療藥物市場：依分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章乾癬治療藥物市場：依應用分類

  • 關節炎
  • 紅皮病
  • 水滴
  • 間擦的
  • 指甲
  • 斑塊
  • 膿皰型

第12章美洲乾癬藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太地區乾癬藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章歐洲、中東和非洲的乾癬藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Celgene Corporation
  • Dr.Reddy's Laboratories
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Leo Pharma AS
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Stiefel Laboratories Inc.
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-434CCDA051B5

The Psoriasis Drugs Market was valued at USD 9.67 billion in 2023, expected to reach USD 10.83 billion in 2024, and is projected to grow at a CAGR of 12.07%, to USD 21.48 billion by 2030.

The scope of psoriasis drugs encompasses a range of treatments designed to manage and alleviate the symptoms associated with psoriasis, a chronic autoimmune condition characterized by the rapid growth of skin cells leading to scaling and inflammation. The necessity of these drugs is underscored by the increasing prevalence of psoriasis globally, which affects millions and can significantly impact quality of life. Applications extend across various drug types including biologics, oral systemic treatments, and topical therapies, each tailored to different severities and types of psoriasis. End-use scope primarily involves hospitals, clinics, and home care settings, with biologics frequently administered in clinical settings due to their complexity.

KEY MARKET STATISTICS
Base Year [2023] USD 9.67 billion
Estimated Year [2024] USD 10.83 billion
Forecast Year [2030] USD 21.48 billion
CAGR (%) 12.07%

Key growth factors influencing the psoriasis drugs market include advancing research in biotechnology leading to targeted therapies, increased healthcare spending, and heightened awareness of psoriasis and its treatment options. Additionally, the expanding pipeline of drugs in various stages of clinical trials presents significant growth opportunities. Notably, the shift towards patient-centric care and the demand for personalized medicine boost the market's potential, as does the rising incidence of psoriasis in developing countries due to urbanization and changing lifestyles.

However, several challenges exist. High costs associated with biologic treatments and stringent regulatory requirements for drug approval pose significant barriers. Moreover, access to medications in low-income regions can be limited, affecting market penetration.

Innovation efforts could focus on developing cost-effective biosimilars, improving the efficacy of existing drugs, and exploring novel delivery systems to enhance patient compliance. There is ample opportunity in digital health integration, such as wearable devices for symptom monitoring, which can facilitate better management. The market is characterized by rapid technological advancements and dynamic shifts towards more holistic and patient-friendly treatment approaches. Companies that leverage these innovations and address the cost accessibility barriers can potentially drive substantial growth and maintain a competitive edge in this evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Psoriasis Drugs Market

The Psoriasis Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of psoriasis
    • Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
    • Ease of process of approval of psoriasis drugs
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Increase in psoriasis research and pipeline drugs
  • Market Challenges
    • Side effects of the medication

Porter's Five Forces: A Strategic Tool for Navigating the Psoriasis Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Psoriasis Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Psoriasis Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Psoriasis Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Psoriasis Drugs Market

A detailed market share analysis in the Psoriasis Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Psoriasis Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Psoriasis Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Psoriasis Drugs Market

A strategic analysis of the Psoriasis Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Psoriasis Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc., Celgene Corporation, Dr.Reddy's Laboratories, Eli Lilly and Company, Johnson & Johnson Services, Inc., Leo Pharma AS, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Stiefel Laboratories Inc., Sun Pharmaceutical Industries Ltd, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Psoriasis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Interleukin Inhibitors and Tumor Necrosis Factor Inhibitor.
  • Based on Type of Treatment, market is studied across Biologic Drugs, Small Molecule Systemic Drugs, and Tropical Therapies.
  • Based on Mechanism of Action, market is studied across Interleukin Inhibitors, PDE4 Inhibitors, and TNF Alpha Inhibitors.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Application, market is studied across Arthritis, Erythrodermic, Guttate, Intertriginous, Nail, Plaque, and Pustular.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of psoriasis
      • 5.1.1.2. Rising geriatric population coupled with growing prevalence of plaque psoriasis and psoriatic arthritis
      • 5.1.1.3. Ease of process of approval of psoriasis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in psoriasis research and pipeline drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of the medication
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Psoriasis Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Interleukin Inhibitors
  • 6.3. Tumor Necrosis Factor Inhibitor

7. Psoriasis Drugs Market, by Type of Treatment

  • 7.1. Introduction
  • 7.2. Biologic Drugs
  • 7.3. Small Molecule Systemic Drugs
  • 7.4. Tropical Therapies

8. Psoriasis Drugs Market, by Mechanism of Action

  • 8.1. Introduction
  • 8.2. Interleukin Inhibitors
  • 8.3. PDE4 Inhibitors
  • 8.4. TNF Alpha Inhibitors

9. Psoriasis Drugs Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Parenteral
  • 9.4. Topical

10. Psoriasis Drugs Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Psoriasis Drugs Market, by Application

  • 11.1. Introduction
  • 11.2. Arthritis
  • 11.3. Erythrodermic
  • 11.4. Guttate
  • 11.5. Intertriginous
  • 11.6. Nail
  • 11.7. Plaque
  • 11.8. Pustular

12. Americas Psoriasis Drugs Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Psoriasis Drugs Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Psoriasis Drugs Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca Plc
  • 4. Bausch Health Companies Inc.
  • 5. Celgene Corporation
  • 6. Dr.Reddy's Laboratories
  • 7. Eli Lilly and Company
  • 8. Johnson & Johnson Services, Inc.
  • 9. Leo Pharma AS
  • 10. Merck & Co., Inc.
  • 11. Novartis International AG
  • 12. Pfizer Inc.
  • 13. Stiefel Laboratories Inc.
  • 14. Sun Pharmaceutical Industries Ltd
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. PSORIASIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. PSORIASIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PSORIASIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PSORIASIS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULE SYSTEMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TROPICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF ALPHA INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTERTRIGINOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PSORIASIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY TYPE OF TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PSORIASIS DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023